National Academy of Medicine expresses concern over use of Russian vaccine candidate EpiVacCorona

1198582

Caracas.- The National Academy of Medicine (ANM) expressed its concern this Tuesday, June 8, at the introduction in the Venezuelan population of products of doubtful scientific credibility, this in relation to the announcements of the government of Nicolás Maduro about the acquisition and the use of the Russian vaccine candidate against COVID-19, the EpiVacCorona.

In a bulletin released this Tuesday, the institution warns that very little is known about the EpiVacCorona, whose scientific design and lack of adequate clinical tests raise concern. As detailed by the National Academy of Medicine, the EpiVacCorona is a ‘minimalist’ biologic based on three small segments (peptides) of spike protein S, which Russian researchers think will be sufficient to confer protection against COVID-19.

“The WHO database indicates that phase 3, which is necessary to determine if the product is truly effective, would take place between November 2020 and September 2021, with the participation of only 3,000 volunteers,” the institution detailed in its bulletin.

READ ALSO

KEYS | What is known about the new Russian vaccine EpiVacCorona

The National Academy of Medicine alludes to the announcement by the Maduro government about the acquisition of 10 million doses of the Russian vaccine candidate, an action that it described as surprising, and for which it stressed that the terms of the contract or scientific information are not known on which the Maduro administration relied to buy the doses of the EpiVacCorona.

On May 4, the vice president of the Maduro government, Delcy Rodríguez, announced the start of clinical trials of the EpiVacCorona in the country, after the Russian ambassador to Venezuela, Sergei Mélik Bagdasárov, applied the drug in a broadcast televised by the state channel VTV.

READ ALSO

Scientist says Russian vaccine EpiVacCorona generates immunity against COVID-19 for one year

‘There is still no evidence of protective efficacy and the number of volunteers may not be enough to detect possible adverse effects. We are struck by the fact that in this case the protocols supported by scientific evidence that were followed with the Sputnik V vaccine were not continued, “said the National Academy of Medicine, which offered its advice for the selection of vaccines that have already demonstrated safety and efficacy. .

See also  Four avenues for improving patient care

Drafting El PitazoVista_3

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.